San Diego Life Sciences Roundup: Amylin Buyout, PDUFA, & More
(Page 2 of 2)
Antibiotic Incentives Now,” also known as the GAIN Act. It provides incentives for the life sciences industry to develop a new generation of antibiotics for treating life-threatening infections caused by drug-resistant pathogens.
—San Diego-based Trovagene (NASDAQ: TROV) said it has agreed to work with scientists at The University of Texas MD Anderson Cancer Center to develop a urine test for detecting KRAS mutations in the genomes of pancreatic cancer patients. Trovagene, which develops trans-renal molecular diagnostics, said a non-invasive urine test would greatly simplify patient monitoring.
—San Diego’s BioSurplus, which provides online listings of used laboratory equipment and provides equipment management services, has expanded its equity round from the $1.5 million disclosed in May to $2.4 million, according to VentureWire. BioSurplus said in May that KI Investment Holdings provided most of the round.
—San Diego-based MediciNova (NASDAQ: MNOV) said it has scheduled an end-of-Phase 2 meeting with the FDA on Oct. 22 to discuss the company’s plans for a late-stage trial of its experimental compound for urgent care treatment of acute asthma. In May, MediciNova reported some mixed results of its mid-stage clinical trials of the drug, which has been designated MN-221. MediciNoval laid out its plans for me earlier this year.
—Qualcomm awarded a total of $30,000 in prize money to Rich Stoner, a research engineer at UC San Diego, for demonstrating an app that could be used to detect signs of autism in 12-month-old infants during a one-day “hackathon and codefest” the company sponsored. The all-day mobile app development competition offered a total of $50,000 in cash prizes to developers in five categories. Stoner got the prize for “best prototype app using facial processing” as well as the $25,000 grand prize for best overall app.